JAKARTA - PT Pyridam Farma Tbk (PYFA), a pharmaceutical company, gained IDR 275.47 billion of net profit in 2022, proliferating 4,928% year-on-year (yoy) from IDR 5.47 billion in 2021. It was further propelled by 1,337% surge in its revenue.

In the 2022 Financial Report published today (6/4), Lee Yan Gwan, President Director of Pyridam Farma, revealed that the sales last year clocked up to IDR 715.42 billion, shifting from IDR 630.53 billion in 2021. The gross and operating profit both reached IDR 250.84 billion and IDR 345.85 billion, both increasing from IDR 244.58 billion and IDR 51.89 billion recorded in the same period in 2021.

In 2022, the sales consisted of revenue from pharmaceutical, aesthetic, and subcontractor services of IDR 847.72 billion, as well as export of pharmaceutical products of IDR 1.07 billion. After the additional charges and cuts of IDR 133.37 billion, the total revenue arrived at IDR 715.42 billion. (LK/ZH)